Literature DB >> 19653986

Aripiprazole treatment of risperidone-induced hyperprolactinemia.

Jing Xu Chen, Yun Ai Su, Shao Li Wang, Qing Tao Bian, Yan Hong Liu, Ning Wang, Fu De Yang, Colin Haile, Thomas R Kosten, Xiang Yang Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19653986     DOI： 10.4088/jcp.08l04671

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  5 in total

Review 1.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.

Authors:  Marrit K de Boer; Stynke Castelein; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Bull       Date:  2015-02-25       Impact factor: 9.306

2.  Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.

Authors:  Zhe Lu; Yaoyao Sun; Yuyanan Zhang; Yu Chen; Liangkun Guo; Yundan Liao; Zhewei Kang; Xiaoyang Feng; Weihua Yue
Journal:  Transl Psychiatry       Date:  2022-07-05       Impact factor: 7.989

Review 3.  Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials.

Authors:  Meiling Meng; Wei Li; Shaowei Zhang; Hongyan Wang; Jianhua Sheng; Jijun Wang; Chunbo Li
Journal:  Shanghai Arch Psychiatry       Date:  2015-02-25

4.  Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level.

Authors:  Pu Zhi; Yanqiong Wang; Wei Quan; Yanli Su; Hui Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-27       Impact factor: 2.570

5.  Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

Authors:  Xianbin Li; Yilang Tang; Chuanyue Wang
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.